ArticleBMC palliative care2025
Prescription of essential medication during the final hospitalization of patients with heart failure or cancer.
Article in BMC palliative care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundFour medication types-opioids, benzodiazepines, anticholinergics, and antipsychotics-have been proposed as essential for patients in their final days, regardless of their primary diagnosis. These drugs are typically prescribed for individuals with cancer who are under specialized palliative care (PC+). However, it is not known whether their usage is equally common for patients with other chronic and progressive conditions, such as heart failure (HF), or for those who are not under specialized palliative care (PC-).
aimTo assess the prescription frequency of each of the four medication types during the final hospitalization of patients with HF and compare it with the prescription frequency in patients with cancer (CA), considering both PC + and PC- patients in each disease group.
methodsA retrospective cohort study included all patients dying in a tertiary hospital between 2016 and 2022. We created three disease groups - "HF," "CA," and "HF&CA" - splitting each of them into two groups, depending on whether they received PC. So there were a total of six groups - "HF PC+", "HF PC-", "CA PC+", "CA PC-", "HF&CA PC+", and "HF&CA PC-".
resultsOf the 3,874 patients, 1,921 (59%) had cancer exclusively, 371 (10%) had heart failure exclusively, and 691 (18%) had both. The median length of stay was 9 days (IQR 2-16). Within each diagnosis group, PC + patients had a higher prescription frequency for each medication type than PC- patients. For example, patients who received PC had 12 times the odds of being prescribed opioids than those who did not receive it (p < 0.05). Among the six groups, the highest prescription frequency of opioids, benzodiazepines, and anticholinergics was seen in the "HF PC+" group and the lowest in the "HF PC-" group. Antipsychotics were prescribed less frequently in the "HF PC-" and the "CA PC-" groups and were mainly prescribed in the "CA PC+" group.
conclusionAcross the diagnostic groups, a notable difference in the prescription of the four medication types was observed between PC + and PC- patients. This difference was more pronounced among patients with HF (without cancer).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.